AR105520A1 - PD-1 BINDING MOLECULES AND SAME USE METHODS - Google Patents

PD-1 BINDING MOLECULES AND SAME USE METHODS

Info

Publication number
AR105520A1
AR105520A1 ARP160102301A ARP160102301A AR105520A1 AR 105520 A1 AR105520 A1 AR 105520A1 AR P160102301 A ARP160102301 A AR P160102301A AR P160102301 A ARP160102301 A AR P160102301A AR 105520 A1 AR105520 A1 AR 105520A1
Authority
AR
Argentina
Prior art keywords
domain
seq
mab
amino acid
acid sequences
Prior art date
Application number
ARP160102301A
Other languages
Spanish (es)
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AR105520A1 publication Critical patent/AR105520A1/en

Links

Abstract

Reivindicación 1: Una molécula de unión a PD-1 anti-humano que comprende un Dominio de Cadena Pasada Variable y un Dominio de Cadena Ligera Variable, caracterizada porque: el Dominio de Cadena Pasada Variable comprende un Dominio CDRH1, un Dominio CDRH2 y un Dominio CDRH3, y el Dominio de Cadena Ligera Variable comprende un Dominio CDRL1, un Dominio CDRL2, y un Dominio CDRL3, en donde: (A) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 1 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 71, SEQ ID Nº 72, y SEQ ID Nº 73; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 1 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 76, SEQ ID Nº 77, y SEQ ID Nº 78; o (B) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 2 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 85, SEQ ID Nº 86, y SEQ ID Nº 87; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 2 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 90, SEQ ID Nº 91, y SEQ ID Nº 92; (C) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 3 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 99, SEQ ID Nº 100, y SEQ ID Nº 101; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 3 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 104, SEQ ID Nº 105, y SEQ ID Nº 106; (D) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 4 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 109, SEQ ID Nº 110, y SEQ ID Nº 111; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 4 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 114, SEQ ID Nº 115, y SEQ ID Nº 116; (E) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 5 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 119, SEQ ID Nº 120, y SEQ ID Nº 121; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 5 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 124, SEQ ID Nº 125, y SEQ ID Nº 126; o (F) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 6 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 129, SEQ ID Nº 130, y SEQ ID Nº 131; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 6 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 134, SEQ ID Nº 135, y SEQ ID Nº 136; o (G) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 7 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 139, SEQ ID Nº 140, y SEQ ID Nº 141; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 7 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 144, SEQ ID Nº 145, y SEQ ID Nº 146; o (H) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 8 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 161, SEQ ID Nº 162, y SEQ ID Nº 163; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 8 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 166, SEQ ID Nº 167, y SEQ ID Nº 168; o (I) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 9 de PD-1, y respectivamente tienen las secuencias de aminoácidos: (SEQ ID Nº 171, SEQ ID Nº 172, y SEQ ID Nº 173; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 9 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 176, SEQ ID Nº 177, y SEQ ID Nº 178; (J) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 10 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 192, SEQ ID Nº 193, y SEQ ID Nº 194; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 10 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 197, SEQ ID Nº 198, y SEQ ID Nº 199; o (K) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 11 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 202, SEQ ID Nº 203, y SEQ ID Nº 204; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 11 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 207, SEQ ID Nº 208, y SEQ ID Nº 209; o (L) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 12 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 212, SEQ ID Nº 213, y SEQ ID Nº 214; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 12 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 217, SEQ ID Nº 218, y SEQ ID Nº 219; o (M) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 13 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 222, SEQ ID Nº 223, y SEQ ID Nº 224; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 13 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 227, SEQ ID Nº 228, y SEQ ID Nº 229; o (N) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 14 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 232, SEQ ID Nº 233, y SEQ ID Nº 234; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 14 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 237, SEQ ID Nº 238, y SEQ ID Nº 239; o (O) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 15 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 242, SEQ ID Nº 243, y SEQ ID Nº 244; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 15 de PD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 247, SEQ ID Nº 248, y SEQ ID Nº 249; o (P) (1) El Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 7(1.2) de hPD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 139, SEQ ID Nº 140, y SEQ ID Nº 141; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 7(1.2) de hPD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 157, SEQ ID Nº 145, y SEQ ID Nº 146; o (Q) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 7(1.3) de hPD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 139, SEQ ID Nº 140, y SEQ ID Nº 141; y 2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR de Cadena Ligera de mAb 7(1.3) de hPD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 157, SEQ ID Nº 158, y SEQ ID Nº 145; o (R) (1) el Dominio CDRH1, Dominio CDRH2, y Dominio CDRH3 son los CDR de Cadena Pesada de mAb 9(2.2) de hPD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 183, SEQ ID Nº 172, y SEQ ID Nº 173; y (2) el Dominio CDRL1, Dominio CDRL2, y Dominio CDRL3 son los CDR, de Cadena Ligera de mAb 9(2.2) de hPD-1, y respectivamente tienen las secuencias de aminoácidos: SEQ ID Nº 188, SEQ ID Nº 189, y SEQ ID Nº 178. Reivindicación 24: la molécula de unión a PD-1 anti-humano de conformidad con la reivindicación 23, caracterizada porque la enfermedad o padecimiento es cáncer o una infección.Claim 1: An anti-human PD-1 binding molecule comprising a Variable Past Chain Domain and a Variable Light Chain Domain, characterized in that: The Variable Past Chain Domain comprises a CDRH1 Domain, a CDRH2 Domain and a Domain CDRH3, and the Variable Light Chain Domain comprises a CDRL1 Domain, a CDRL2 Domain, and a CDRL3 Domain, where: (A) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 1 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 71, SEQ ID No. 72, and SEQ ID No. 73; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 1 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 76, SEQ ID No. 77, and SEQ ID No. 78; or (B) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 2 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 85, SEQ ID No. 86, and SEQ ID No. 87; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 2 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 90, SEQ ID No. 91, and SEQ ID No. 92; (C) (1) Domain CDRH1, Domain CDRH2, and Domain CDRH3 are the Heavy Chain CDRs of mAb 3 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 99, SEQ ID No. 100, and SEQ ID No. 101; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 3 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 104, SEQ ID No. 105, and SEQ ID No. 106; (D) (1) Domain CDRH1, Domain CDRH2, and Domain CDRH3 are the Heavy Chain CDRs of mAb 4 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 109, SEQ ID No. 110, and SEQ ID No. 111; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 4 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 114, SEQ ID No. 115, and SEQ ID No. 116; (E) (1) Domain CDRH1, Domain CDRH2, and Domain CDRH3 are the Heavy Chain CDRs of mAb 5 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 119, SEQ ID No. 120, and SEQ ID No. 121; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 5 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 124, SEQ ID No. 125, and SEQ ID No. 126; or (F) (1) Domain CDRH1, Domain CDRH2, and Domain CDRH3 are the Heavy Chain CDRs of mAb 6 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 129, SEQ ID No. 130, and SEQ ID No. 131; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 6 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 134, SEQ ID No. 135, and SEQ ID No. 136; or (G) (1) Domain CDRH1, Domain CDRH2, and Domain CDRH3 are the Heavy Chain CDRs of mAb 7 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 139, SEQ ID No. 140, and SEQ ID No. 141; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 7 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 144, SEQ ID No. 145, and SEQ ID No. 146; or (H) (1) Domain CDRH1, Domain CDRH2, and Domain CDRH3 are the Heavy Chain CDRs of mAb 8 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 161, SEQ ID No. 162, and SEQ ID No. 163; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 8 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 166, SEQ ID No. 167, and SEQ ID No. 168; or (I) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 9 of PD-1, and respectively have the amino acid sequences: (SEQ ID No. 171, SEQ ID No. 172, and SEQ ID No. 173; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 9 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 176, SEQ ID No. 177, and SEQ ID No. 178; (J) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 10 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 192 , SEQ ID No. 193, and SEQ ID No. 194; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 10 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 197, SEQ ID No. 198, and SEQ ID No. 199; or (K) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 11 of PD-1, and respectively have the sequences of amino acids: SEQ ID No. 202, SEQ ID No. 203, and SEQ ID No. 204; and (2) Domain CDRL1, Domain CDRL2, and Domain CDRL3 are the Light Chain CDRs of mAb 11 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 207, SEQ ID No. 208, and SEQ ID No. 209; or (L) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 12 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 212, SEQ ID No. 213, and SEQ ID No. 214; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 12 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 217, SEQ ID No. 218, and SEQ ID No. 219; or (M) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 13 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 222, SEQ ID No. 223, and SEQ ID No. 224; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 13 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 227, SEQ ID No. 228, and SEQ ID No. 229; or (N) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 14 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 232, SEQ ID No. 233, and SEQ ID No. 234; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 14 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 237, SEQ ID No. 238, and SEQ ID No. 239; or (O) (1) Domain CDRH1, Domain CDRH2, and Domain CDRH3 are the Heavy Chain CDRs of mAb 15 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 242, SEQ ID No. 243, and SEQ ID No. 244; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 15 of PD-1, and respectively have the amino acid sequences: SEQ ID No. 247, SEQ ID No. 248, and SEQ ID No. 249; or (P) (1) The CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 7 (1.2) of hPD-1, and respectively have the amino acid sequences: SEQ ID No. 139, SEQ ID No. 140, and SEQ ID No. 141; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 7 (1.2) of hPD-1, and respectively have the amino acid sequences: SEQ ID No. 157, SEQ ID No. 145, and SEQ ID No. 146; or (Q) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 7 (1.3) of hPD-1, and respectively have the amino acid sequences: SEQ ID No. 139, SEQ ID No. 140, and SEQ ID No. 141; and 2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of mAb 7 (1.3) of hPD-1, and respectively have the amino acid sequences: SEQ ID No. 157, SEQ ID No. 158, and SEQ ID No. 145; or (R) (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of mAb 9 (2.2) of hPD-1, and respectively have the amino acid sequences: SEQ ID No. 183, SEQ ID No. 172, and SEQ ID No. 173; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the CDR, Light Chain mAb 9 (2.2) of hPD-1, and respectively have the amino acid sequences: SEQ ID No. 188, SEQ ID No. 189, and SEQ ID No. 178. Claim 24: The anti-human PD-1 binding molecule according to claim 23, characterized in that the disease or condition is cancer or an infection.

ARP160102301A 2015-07-30 2016-07-28 PD-1 BINDING MOLECULES AND SAME USE METHODS AR105520A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562198867P 2015-07-30 2015-07-30

Publications (1)

Publication Number Publication Date
AR105520A1 true AR105520A1 (en) 2017-10-11

Family

ID=60244687

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160102301A AR105520A1 (en) 2015-07-30 2016-07-28 PD-1 BINDING MOLECULES AND SAME USE METHODS
ARP200102705A AR120117A2 (en) 2015-07-30 2020-09-29 PD-1 BINDING MOLECULES AND METHODS OF USE THEREOF

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200102705A AR120117A2 (en) 2015-07-30 2020-09-29 PD-1 BINDING MOLECULES AND METHODS OF USE THEREOF

Country Status (2)

Country Link
AR (2) AR105520A1 (en)
MA (1) MA47137B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112543767A (en) * 2018-07-11 2021-03-23 卡尔医学有限公司 PD1-4-1BBL variant fusion proteins and methods of use thereof
CN116854820A (en) * 2023-06-26 2023-10-10 华中科技大学同济医学院附属协和医院 PD-1 non-blocking scavenging antibodies and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112543767A (en) * 2018-07-11 2021-03-23 卡尔医学有限公司 PD1-4-1BBL variant fusion proteins and methods of use thereof
CN116854820A (en) * 2023-06-26 2023-10-10 华中科技大学同济医学院附属协和医院 PD-1 non-blocking scavenging antibodies and uses thereof
CN116854820B (en) * 2023-06-26 2024-02-06 华中科技大学同济医学院附属协和医院 PD-1 non-blocking scavenging antibodies and uses thereof

Also Published As

Publication number Publication date
MA47137B1 (en) 2021-08-31
AR120117A2 (en) 2022-02-02
MA47137A (en) 2019-10-30

Similar Documents

Publication Publication Date Title
IL257281A (en) Anti-pd-1 antibodies and methods of use thereof
PE20180927A1 (en) LAG-3 BINDING MOLECULES AND METHODS OF USE OF THEM
PE20161033A1 (en) GITR ANTIGEN BINDING PROTEINS
AR086044A1 (en) ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME
PE20142242A1 (en) ANTI-CD27 HUMAN ANTIBODIES, METHODS, AND USES
HRP20201503T1 (en) Molecules with specificity for cd45 and cd79
JP2020500538A5 (en)
PE20191131A1 (en) ACTIVABLE CYTOTOXIC T LYMPHOCYTE 4 ANTI ANTIGEN (CTLA-4) ANTIBODIES AND THEIR USES
RS54846B1 (en) Novel anti-dr5 antibody
AR117911A2 (en) ANTI-158P1D7 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, DRUG-ANTIBODY CONJUGATE, PHARMACEUTICAL COMPOSITION AND ITS USES
AR096687A1 (en) ANTI-FCRH5 ANTIBODIES
PE20211863A1 (en) BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING CLONE 212 ANTI-FAP
CL2013003140A1 (en) An isolated human monoclonal antibody or antigen binding fragment thereof that binds to human masp-2; nucleic acid molecule, expression cassette, cell that expresses it, method of production, composition that contains it, article that contains it.
ES2571129T3 (en) Humanized anti-CTLA4 antibodies
ES2631135T3 (en) Human antigen binding proteins that bind to beta-Klotho, FGF receptors and complexes thereof
CL2010001544A1 (en) Humanized monoclonal antibody or binding fragment that binds and neutralizes the human vascular endothelial growth factor (hvegf); composition that includes it; nucleic acid coding; vector; host cell; its use to treat or prevent a disease mediated by vegf; and hybridoma.
RU2021103288A (en) MOLECULES SPECIFIC FOR CD79 and CD22
AR066164A1 (en) HUMAN PROTEINS OF UNION TO ANTIGENS OF THE STIMULATING FACTOR OF COLONIES OF MEGACARIOCITOS-MACROFAGOS (GM-CSF)
PE20221151A1 (en) ANTI-CD96 ANTIBODIES AND THEIR METHODS OF USE
NZ603972A (en) Anti-fgfr2 antibodies
AR086579A1 (en) PROTEINS OF UNION TO ANTIGEN
AR078778A1 (en) IL-23 ANTIGEN UNION PROTEINS
ES2430068T3 (en) Antigen-binding proteins of the epidermal growth factor type heparin-binding growth factor
PE20120554A1 (en) POLYPEPTIDES AND METHOD OF TREATMENT
PE20170687A1 (en) BINDING PROTEINS TO CD127